Eur Rev Med Pharmacol Sci 2022; 26 (21): 7967-7973

DOI: 10.26355/eurrev_202211_30149

Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study

R. Foti, G. Amato, A. Benenati, Y. Dal Bosco, R. Piazza, C. Gagliano, R. Foti, S. Bellofiore, E. Visalli

Rheumatology Unit, San Marco Hospital, Policlinico University of Catania, Catania, Italy. elivisa21@gmail.com


OBJECTIVE: This study aims at evaluating the disease progression, specifically in terms of cardiopulmonary function, in a group of consecutively enrolled systemic sclerosis (SSc) patients treated with the approved iloprost regimen.

PATIENTS AND METHODS: A retrospective observational study was performed on 68 SSc patients treated with 5-6 infusions of iloprost per month for 6 hours per day at a dosage of 0.5-2.0 ng/kg/min through a portable syringe pump. All patients were evaluated for modified Rodnan skin score, systolic pulmonary arterial pressure, tricuspid annular plane systolic excursion, diffusing capacity of the lungs for carbon monoxide, forced vital capacity, alveolar volume, diffusing capacity of the lungs for carbon monoxide/alveolar volume, pro-brain natriuretic peptide (pBNP), New York Heart Association class, and the presence or absence of digital ulcers (DUs).

RESULTS: After a follow-up period of 9.9±2.9 years, all patients improved in frequency and severity of the Raynaud phenomenon and showed a stabilization or improvement of cardiopulmonary parameters. The pulmonary arterial pressure and pBNP improved significantly from baseline (30.91±6.4 mmHg vs. 27.36±7.1 mmHg, and 97.20±69.3 pg/ml vs. 66.65±44.3 pg/ml, respectively; p<0.0001 for both). A significant improvement was observed in the modified Rodnan skin score in 57 patients who continued the treatment during the entire follow-up (5.09±5.7 vs. 3.30±4.2, p<0.0001).

CONCLUSIONS: Despite the retrospective design and the lack of a control group, the regular and continued administration of iloprost maintained the stability of the cardiopulmonary and cutaneous parameters in SSc. It significantly reduced pBNP levels, a prognostic cardiac biomarker of SSc. Future research should be addressed to demonstrate a stronger causality of this effect.

Free PDF Download

To cite this article

R. Foti, G. Amato, A. Benenati, Y. Dal Bosco, R. Piazza, C. Gagliano, R. Foti, S. Bellofiore, E. Visalli
Intravenous iloprost in systemic sclerosis and its effect in cardiopulmonary function: a retrospective observational study

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 21
Pages: 7967-7973
DOI: 10.26355/eurrev_202211_30149